Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.18 CHF | +7.32% | +3.31% | +45.05% |
Apr. 17 | Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member | CI |
Mar. 19 | Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 35.98M 38.62M 35.21M | Sales 2025 * | 25.95M 27.86M 25.4M | Capitalization | 127M 137M 125M |
---|---|---|---|---|---|
Net income 2024 * | 13M 13.95M 12.72M | Net income 2025 * | 4M 4.29M 3.92M | EV / Sales 2024 * | 4.35 x |
Net Debt 2024 * | 29.11M 31.24M 28.49M | Net Debt 2025 * | 2M 2.15M 1.96M | EV / Sales 2025 * | 4.99 x |
P/E ratio 2024 * |
8.77
x | P/E ratio 2025 * |
29.3
x | Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.09% |
Latest transcript on Newron Pharmaceuticals S.p.A.
1 day | +7.32% | ||
1 week | +3.31% | ||
Current month | -7.47% | ||
1 month | -4.01% | ||
3 months | -13.08% | ||
6 months | +52.77% | ||
Current year | +45.05% |
Managers | Title | Age | Since |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 12-05-14 |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 07-12-31 | |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Ulrich Köstlin
CHM | Chairman | 71 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 7.18 | +7.32% | 35 338 |
24-04-25 | 6.69 | -4.43% | 63,462 |
24-04-24 | 7 | 0.00% | 43,337 |
24-04-23 | 7 | -2.51% | 32,096 |
24-04-22 | 7.18 | +3.31% | 62,322 |
Delayed Quote Swiss Exchange, April 26, 2024 at 05:51 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+45.05% | 136M | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-21.76% | 29.48B | |
+55.26% | 25.43B | |
-14.78% | 15.59B | |
-18.49% | 11.49B | |
-15.61% | 11.1B | |
-44.02% | 11.3B | |
+4.42% | 8.75B |
- Stock Market
- Equities
- NWRN Stock